Authors
Latest:
Real-World Data Networks: Automating & Reducing the Burden of Clinical Studies and RegistriesMon, Aug 8, 2022 1:00pm EST | 10:00am PST | 7:00pm CEST Real-world data networks are changing how data is collected and leveraged for evidence generation. A tech-enabled platform approach can significantly automate and reduce the burden of clinical study programs and registries, improve site and patient engagement and lower costs.
Latest:
Reinventing the Role of Medical AffairsAs digital technologies transform drug development and marketing, a retooled medical affairs function can be a competitive differentiator.
Latest:
Upward Mobility: Optimizing Your Pharma T-ProfileWith lessons and perspectives from the field, the importance of harnessing the right combination of skills to advance up and across career ladders is explored.
Latest:
Customer Experience: A Buzz Term or a Source of Real Commercial Value?Exploring the importance of a customer experience strategy (CXM) through a case study of a life science tools company.
Latest:
Beyond KOL Marketing: Tapping Digital Opinion InfluencersWith healthcare professionals and patients now collecting much of their information online, there is new opportunity for “digital opinion influencers” to amplify traditional KOL messaging-or create their own.
Latest:
Specialty Pharma and Patient Privacy ProtectionPamela Buffone from Privacy Analytics discusses growth in the specialty pharma sector and making patient data protection a top priority.
Latest:
Launching a New Drug: An Overview of Common MistakesJackie DeAngelis outlines three common mistakes that hinder access attainment when launching a new drug.
Latest:
South Florida Delivers on Pharma-Friendly DistributionThis article discusses the supply chain benefits of pharma companies distributing from South Florida.
Latest:
Harnessing the Value of AI In Customer EngagementBy using correct data and pertinent ML algorithms, customer engagement leaders can identify deep insights into customer behavior and make the right interventions to transform the customer experience.
Latest:
The Reluctant Customer: Using Personas to Improve ComplianceConsumers of life sciences products are reluctant customers, and this reluctance can turn into non-compliance. Organizations and providers need to understand patients at a human level, and what will motivate them to stay with a treatment plan, writes John Pagliuca.
Latest:
Could Valeant Pharmaceuticals Have Gifted Teva its "Biggest Commercial Hope"?Intellectual property analysis of one recently approved drug shows how Valiant might have missed out on at least one vital acquisition opportunity. Duncan Clark reports.
Latest:
Ukraine: Protecting Investments through Entry Agreements Between Pharma and GovernmentLana Sinichkina, Kateryna Oliinyk and Yevgeniya Ocheretko discuss how the recent settlement between Gilead and Ukraine's Ministry of Health could promote earlier market access in the country.
Latest:
Charting an Effective Big Data StrategyBig data has proven to be a valuable business asset, but using it to gain competitive advantage requires the right combination of strategy, technology and execution, write Mahmood Majeed, Vickye Jain, and Sandeep Varma.
Latest:
News Spotlight: PharmaPharm Exec’s 13th Annual Press Audit audit reveals a tonal undercurrent in sync with an industry unable to escape the glare of scrutiny.
Latest:
Opioid Litigation: Evading the Widening CrosshairsThe role of insurance and risk management in protecting middle-market distributors from the growing opioid multi-district litigation (MDL).
Latest:
Can AI Improve Sales Productivity in Pharma?With the physician-access climate as daunting as ever for sales reps, four best practices in implementing artificial intelligence-based technology to help achieve engagement wins are explored.
Latest:
Building a Digital Health InfrastructureOutlining the four core elements pharma companies need to lay the foundation for a solid digital health infrastructure.
Latest:
Leveraging Health IT to Improve Drug DevelopmentThe FDA's Mary Ann Slack outlines how the Agency is working to adopt electronic practices by initiating efforts to simplify the submission process for new drug and generic drug applications.
